Morning Overview on MSN
Human gut microbes made mice brains act more like primates
Scientists have long suspected that the trillions of microbes in our intestines do more than digest lunch, but new work goes ...
Using ribosome engineering (RE), researchers from Shinshu University introduced mutations affecting the protein synthesis ...
In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...
Researchers reveal a novel natural “decoy receptor” that protects against inflammatory bowel disease
A research team led by Prof. QIAN Youcun from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences identified a new member of the human IL -17 receptor ...
Researchers have discovered a way to help aging intestines heal themselves using CAR T-cell therapy. By targeting senescent ...
Scientists have uncovered a gut-specific epigenetic aging mechanism that links inflammation and iron imbalance to cancer risk ...
A new study has produced strong evidence that red meat consumption is a trigger for inflammatory bowel disease (IBD), demonstrating how it alters gut bacteria and immune activity in ways that worsen ...
The US humorist Christopher Morley once described the human body as “an ingenious assembly of portable plumbing”. He wasn’t wrong: from our cardiovascular and lymphatic systems to our guts and urinary ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
While in vivo animal models are commonly employed for pharmacokinetic studies, they are often expensive, low in throughpu,t and typically fail to accurately replicate key characteristics of the human ...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback